Welcome to our dedicated page for Alimera Sciences news (Ticker: ALIM), a resource for investors and traders seeking the latest updates and insights on Alimera Sciences stock.
Alimera Sciences, Inc. (NASDAQ: ALIM) is a leading global pharmaceutical company committed to advancing retinal health. Founded in June 2003, the company specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. Alimera's primary focus is on diseases affecting the retina, particularly those that are not well managed by current therapies. The company's flagship product, ILUVIEN, is a sustained-release intravitreal implant used for the treatment of diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) outside the U.S.
ILUVIEN utilizes CONTINUOUS MICRODOSING™ technology, releasing sub-microgram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months. This technology helps to reduce disease recurrence, thereby enabling patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S. and multiple international markets, including 17 European countries, China, and regions in the Middle East.
Recently, Alimera announced positive data from several clinical studies, such as the PALADIN study, which evaluated the long-term safety of ILUVIEN in treating DME. The company also made headlines by completing enrollment for the Synchronicity Study, focusing on YUTIQ, another fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis.
Moreover, Alimera continues to expand its executive team to strengthen its financial and operational capabilities. Elliot Maltz, C.P.A., has been named as the new Chief Financial Officer to drive growth and improve cash flow. The company's European operations are managed through its subsidiary, Alimera Sciences Limited, based in London.
Financially, Alimera Sciences has shown robust growth. In Q4 2023, the company reported net revenues of $26.3 million, an 88% increase compared to the same period in 2022. For the full year 2023, net revenues were up 49% to $80.8 million. This growth is a testament to the successful commercialization of ILUVIEN and YUTIQ.
Looking ahead, Alimera aims to further its mission of being invaluable to patients, physicians, and partners concerned with retinal health. The company is actively involved in numerous clinical studies and regulatory efforts to expand the therapeutic indications for its products, ensuring continued innovation and improved patient outcomes.
For more information, please visit www.alimerasciences.com.
Alimera Sciences (Nasdaq: ALIM) presented findings from the PALADIN Phase 4 Safety Study at the annual American Academy of Ophthalmology conference. The study reveals that patients with diabetic macular edema (DME) treated with the ILUVIEN® implant experienced a 46% reduction in additional therapies required compared to other treatments. Notably, 25% remained treatment-free for 36 months, and patients showed significant improvements in visual acuity and retinal thickness. This data reinforces ILUVIEN's effectiveness in reducing treatment burdens and enhancing patient outcomes in DME management.
Alimera Sciences (Nasdaq: ALIM) announced an agreement with Jaeb Center for Health Research to conduct a clinical trial evaluating ILUVIEN versus observation in preventing vision loss from radiation retinopathy. The trial will involve 600 participants receiving plaque brachytherapy for choroidal melanoma, beginning in Q1 2023. The study aims to prevent or reduce macular edema and vision complications following radiation therapy. Notably, ILUVIEN is already approved for treating diabetic macular edema and has shown promising outcomes in other indications.
Alimera Sciences has received unrestricted reimbursement approval for its ILUVIEN implant in Ireland, aimed at treating non-infectious uveitis affecting the posterior segment of the eye. The Health Service Executive and National Centre for Pharmacoeconomics granted this approval, expanding the availability of ILUVIEN across all direct and key distributor markets. ILUVIEN's sustained-release technology allows for reduced disease recurrence, benefiting patients with fewer injections.
Alimera Sciences announces the presentation of positive findings from the RIVER study during the EURETINA 2022 congress in Germany. More than 20 scientific abstracts related to ILUVIEN® (fluocinolone acetonide intravitreal implant) will be showcased, reinforcing its efficacy in treating diabetic macular edema (DME). ILUVIEN is known for its continuous microdosing technology, providing a sustained release for up to 36 months. The product is approved in multiple regions, including the U.S. and various European countries, for patients who have not had a significant rise in intraocular pressure.
Alimera Sciences (Nasdaq: ALIM), a global pharmaceutical firm focused on retinal health, announced that CEO Rick Eiswirth will present at the HC Wainwright 2nd Annual Ophthalmology Conference on August 17, 2022. The presentation will be available on demand starting at 7:00 AM ET. Additionally, Alimera's management will hold one-on-one meetings with registered investors during the conference. This engagement highlights Alimera's commitment to enhancing vision care and its ongoing relationship with the investment community.
Alimera Sciences has received reimbursement approval without label restrictions for its ILUVIEN® (fluocinolone acetonide) implant in Portugal, as granted by INFARMED. The company plans to launch the product in Q3 2022, expanding its market presence in treating non-infectious uveitis affecting the posterior segment.
CEO Rick Eiswirth stated that this marks a significant step in making ILUVIEN accessible to patients across various markets, enhancing treatment options for chronic inflammatory conditions.
Alimera Sciences (Nasdaq: ALIM) reported second quarter 2022 financial results showing a consolidated net product revenue of $14.6 million, a 36% increase from Q2 2021. U.S. net product revenue rose 53%, driven by increased physician access and patient flow. However, total consolidated net revenue fell 33% due to prior licensing revenue. The company experienced a net loss of $3.1 million and had cash and equivalents of $7.9 million as of June 30, 2022. Alimera expects growth from ILUVIEN’s new pricing and reimbursement in Spain, Italy, and France.
Alimera Sciences recently presented promising data from the PALADIN Phase 4 Study at the ASRS conference, highlighting the effectiveness of ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg in treating diabetic macular edema (DME). The study confirms ILUVIEN's safety and its ability to reduce treatment frequency while enhancing visual acuity. Key findings include an average vision gain of 4.5 ETDRS letters post-treatment and reduced retinal thickness variability.
All outcomes reflect ILUVIEN's potential as a durable treatment option.
Alimera Sciences (Nasdaq: ALIM) will announce its second quarter financial results on July 27, 2022, before market opening. A conference call will be held at 9:00 AM ET to discuss the results and provide updates on corporate developments. Participants can pre-register for the call via the company's website. A webcast replay will be accessible one hour post-call through October 27, 2022. Alimera is dedicated to improving retinal health and vision.
Alimera Sciences announces the upcoming launch of ILUVIEN in France for treating non-infectious posterior uveitis, partnering with Horus Pharma. This product, which recently received pricing and reimbursement approval, aims to reduce disease recurrence. ILUVIEN is already successful in treating diabetic macular edema and is now expanding to address uveitis, a leading cause of blindness. This launch marks a significant achievement in the company’s European strategy, expanding its market presence in major countries.
FAQ
What is the current stock price of Alimera Sciences (ALIM)?
What is the market cap of Alimera Sciences (ALIM)?
What is Alimera Sciences, Inc. specialized in?
What is ILUVIEN?
Where is Alimera Sciences headquartered?
What are the latest financial results for Alimera Sciences?
Who is the new Chief Financial Officer of Alimera Sciences?
What recent clinical studies has Alimera Sciences completed?
In which regions is ILUVIEN approved?
What is the mission of Alimera Sciences?
What technology does ILUVIEN utilize?
Where can I find more information about Alimera Sciences?
